Evaluation of the efficacy of rutin, rutin nanocrystals, and rutin spanlastics nanoparticles as antitumor and antioxidant drug delivery systems Authors: Badriyah S. Alotaibi, Thanaa A. El-Masry, Maisra M. El-Bouseary, Enas I. El Zahaby, Eman Wahsh, Asmaa Saleh, Ahlam Mansour Sultan, Manal E. Alosaimi, Maysa M. F. El-Nagar Published: 2026 ABSTRACT Flavonoids comprise an exclusive class of biomolecules with extensive therapeutic features. Rutin is one of the flavonoids that has antioxidant, anticancer, and other pharmacological actions, but its clinical use is deterred by poor solubility, poor bioavailability, and incomplete absorption. Development of nanotechnology-based delivery platforms is a promising solution to counter these issues. We evaluated the antioxidant and anticancer properties of nanocrystals and spanlastic nanoparticles of rutin against the human breast adenocarcinoma cell line MCF-7 to establish effective delivery methods with improved therapeutic efficacy. The physicochemical characteristics of the nano-formulations were investigated through particle size and zeta potential measurement, Fourier Transform Infrared spectroscopy (FTIR), transmission electron microscopy (TEM), scanning electron microscopy (SEM), electronic bandgap energy, and dissolution behavior. Antioxidant activity was investigated through DPPH and ABTS radical scavenger assays. Anticancer potential was established through a viability assay, cell cycle analysis, dual labeling with annexin-V/propidium iodide (PI) (using fluorescence-activated flow cytometric methods), and Caspase 3 activity. Rutin spanlastic nanoparticles showed a considerably smaller particle size, homogeneous dispersion, and negative zeta potential, indicating stability. Rutin spanlastic nanoparticles exhibited greater antioxidant activity compared with free rutin and rutin nanocrystals, as manifested through stronger inhibition of the viability of MCF-7 cells, stronger induction of apoptosis (annexin-V/PI double staining and Caspase 3 activity), and significant G1/0 phase cell cycle arrest. These observations imply an increased solubilization and elastovesicular behaviour of spanlastic nanoparticles with enhanced bioactivity of rutin. In conclusion, rutin spanlastic nanoparticles are an efficient delivery vehicle compared to rutin nanocrystals or free rutin in amplifying both antioxidant and anticancer activity, hence warranting further in vivo experiments to treat breast carcinoma.Graphical abstract Introduction Cancer is itself a multifactorial disease characterized by uncontrolled cell growth, invasion of tissues, and metastasis. Inflammation has also been reported to be a signature of cancer; chronic inflammatory diseases create a microenvironment high in cytokines, chemokines, and reactive oxygen species (ROS), and that favors genetic instability, initiation, and tumor development [1]. Breast cancer is a disease in which abnormal cells in the breast grow uncontrollably and form tumors. If left untreated, the tumors will invade the body and then become fatal [2]. According to the theme of the WHO initiative, “No one should face breast cancer alone,” trying to find a treatment for breast cancer is a priority and deserves all efforts until it is achieved. WHO noted on 13 March 2024 that 2.3 million women were newly diagnosed with breast cancer, and 670,000 deaths occurred globally in 2022. It is the most prevalent cancer in the world, causing one in every eight instances among both men and women, one-quarter of female cancers, and 70% of deaths in resource-limited areas. Regarding breast cancer, pro-inflammatory mediators and oxidative stress cause damage to nucleic acids, lipids, and proteins that severely disrupt cellular function and contribute to tumour growth. Disturbance of homeostasis between ROS formation and antioxidant defense results in the subsequent oxidative stress as an underlying causative agent of tumour treatment resistance and carcinogenesis. Oxidative stress induces many diseases, and the level of antioxidative enzymes is usually low in cancer patients [3]. Rutin is a naturally occurring flavonoid with several pharmacologic actions such as antioxidant, anti-inflammatory, anti-viral, and anti-tumor [4]. Rutin is found naturally in buckwheat, spinach, tomato plant leaves, apples, onions, and tea. It is also found in citrus fruits, berries, and asparagus, and is therefore one of the most common plant flavonoids [5]. In studies, rutin exhibited protective effects against various diseases induced especially by oxidative stress and lipid peroxidation, depending on its anti-inflammatory, antioxidant, anti-hypertensive, anti-apoptotic, anti-autophagic, and neuroprotective activity [6–8]. Rutin can be considered a non-oxidative and non-toxic molecule [9]. In the last several years, in vivo and in vitro research on rutin demonstrated that rutin has several pharmacological activities [10]. For instance, multi-target activities and the molecular mechanism of rutin in opposition to triple-negative breast cancer (TNBC) were confirmed. The result of a study presents a theoretical basis for rutin as a prospective compound in the therapy of breast cancer [8]. The medicinal value of rutin is limited by its low water solubility, low bioavailability, and sensitivity towards degradation. Besides, it is characterized by rapid metabolism and poor permeability across biological membranes, which greatly restricts its therapeutic application. Many measures, such as cyclodextrin complexes, solvates, and nanoparticles, have been utilized to improve its oral bioavailability and physicochemical properties to overcome the limitations [11, 12]. A major challenge in treating malignant tumors with drugs is ensuring sufficient drug levels reach cancer cells while minimizing side effects from systemic administration. To address this issue, researchers have turned to nanotechnology to take advantage of the small size of the formulation for passive targeting of tumor cells. Nano-scale drug delivery systems can easily reach inside malignant tumors and accumulate therein owing to a lack of lymphatic drainage, hence are extremely useful for cancer treatment [13]. Cancer nanotechnology offers high specificity and improved drug entrapment and tolerability compared with conventional chemotherapeutic treatments [14]. Other advantages include high surface area, which facilitates drug dissolution, appropriate cellular uptake owing to small particle size, improved circulation in the bloodstream, and improved physical stability [15, 16]. Lipid-based nanocarriers, notably liposomes, offer a strategic platform for advanced drug delivery. Their capacity to co-encapsulate and protect the drug from degradation, coupled with mechanisms for localized release, directly addresses the challenges of treating certain diseases [17]. Niosomes are vesicular drug delivery systems composed of self-associated non-ionic surfactants, which have gained much attention because of their chemical stability and potential to improve drug delivery to various organs. Spanlastics, or elastic niosomes, are a relatively novel addition to vesicle-based drug delivery methods [18]. They are similar to spanlastics, but in addition to the bilayer, they also incorporate an edge activator, enhancing both elasticity and deformability, thus allowing increased drug permeation across biological membranes [19]. As a result, spanlastic formulations expand bio-availability and therapeutic efficacy. The type of edge activator also influences particle size, with Tween 80 producing the smallest particles [20]. Additionally, it was reported that spanlastics enhances the bioavailability of medicine via its protection from the biological matrix, and delaying its clearance from systemic circulation [21]. Another example of nanometer-sized particles is a nanocrystal (NC), which is composed entirely of pharmacological ingredients stabilized with appropriate stabilizers [22]. In comparison to other carrier-based nanoparticles, NCs attain high drug loading, resulting in lower doses while improving bioavailability and safety. Since organic solvents are not frequently used, nano-composites are typically solvent-free and less harmful [23]. Their improved solubility and dissolution rate further enhance pharmacokinetics and bio-distribution. Their compact size, vast surface area, and unique physicochemical characteristics make them extremely hopeful for cancer therapy [23]. A comprehensive understanding of the band gap and dissolution kinetics is central to the rational design of modern, high-performance pharmaceutical formulations, particularly for nano-enabled and poorly water-soluble drug delivery systems. For instance, precise control over the band gap achieved through compositional tuning, as demonstrated in novel semiconductor nanocrystals like Cu3VSxSe4 − x and polymer composites like PVDF-copper complexes, directly determines their efficacy as photosensitizers in photodynamic therapy or as generators of reactive oxygen species [24, 25]. In the same context, the dissolution process plays a great role in the pharmaceutical industry. The dissolution kinetics is considered as an essential tool to enhance experimental work characterization; the dissolution models provide essential information for both design and optimization, in addition to a feedback control strategy. The application of advanced modeling based on the Noyes-Whitney equation allows for the precise prediction of dissolution behavior, linking critical attributes like particle size distribution and morphology to the dissolution rate of poorly soluble APIs [26]. Therefore, while the anticancer activity of the rutin itself has been documented, our work provides new insights into the therapeutic advantage conferred by above mensioned nanocarriers, highlighting their significance for drug delivery and anticancer research. The main objective of our present study was to evaluate and compare the antioxidant and anticancer potential of rutin in the forms of nanocrystals and spanlastic nanoparticles against the breast cancer cell line MCF-7 (Michigan Cancer Foundation-7). The evaluation aimed to determine the best nanoformulation and to reflect on the potential of nanocarrier-based delivery in enhancing the therapeutic potential of rutin. Materials and methods Materials Rutin powder was a kind gift from Kahira Pharmaceuticals and Chemical Industries Company, Cairo, Egypt. Tween 80, Span 80, Polronic F-127, Methanol HPLC grade, and Deionized water were obtained from El Naser Pharmaceutical Chemicals, Egypt; Oxford laboratory, India, BASF Corporation, USA, Fisher, England, and Stakpure, Waters, Milford, USA, respectively. Every other reagent was of high analytical quality. Methods Preparation of nanoparticles Spanlastic method Spanlatic was prepared by a slight modification of a previously published method [23, 24]. Rutin (20 mg) was dissolved in the least amount of methanol, then a mixture of Pluronic F-127 (50 mg) and Span 80 (400 mg) was allowed to melt (70 °C) utilizing a hot magnetic plate (Stuart, Caliber Scientific USA). Alcoholic rutin solution was added to the molten mixture with continuous stirring (300 rpm) for 5 min. A preheated 2% tween solution (70 °C) was added drop-wise to the previously melted rutin mixture, equilibrated for 30 min on a magnetic stirrer (300 rpm). The colloidal dispersion was subjected to ultrasonic treatment (Sonic Vibra Cell, USA) for 2 min (10-s pulse and 10-s pause) at 60% amplitude (130 W). The ratio between Span 80 and Tween 80 was selected to be (4:1) based on previously published methods to encapsulate a poorly soluble class II drug. Decreasing the ratio between surface active agent and edge activator to (1:1) can decrease the % EE [27, 28]. Nanocrystals method Nanocrystals were prepared simply by the anti-solvent method [29]. Rutin (100 mg) was dissolved in 5 ml methanol, then the alcoholic solution was injected drop wise into 25 ml of 1% tween solution with continuous stirring on a magnetic stirrer (Stuart, Caliber Scientific USA) at 400 rpm for 30 min, the colloid dispersion was subjected to homogenizer)DAIHAN scientific( at 10,000 rpm for 5 min followed by ultra sound treatment (Sonic Vibra Cell, USA) at 60% amplitude (130 W) for 5 min (10 s pulse and 10 s pause). Characterization of spanlastic and nanocrystals formulation The zeta potential, polydispersity index (PDI), and hydrodynamic diameter were examined using Zetasizer from Malvern Instruments (Malvern, UK). The samples were suitably diluted with deionized water and then allowed to equilibrate for 5 min before analysis. Drug content of rutin nanocrystals and rutin spanlastic was investigated utilizing a spectrophotometric method at ʎmax 257 nm (Shimadzu UV–VIS spectrophotometer, UV-1900I, Japan). Experiments were conducted in triplicate (n = 3) [30, 31]. A concentrated alcoholic stock solution of rutin was prepared by dissolving 10 mg rutin and dissolved in 10 ml methanol (1 mg/ml). A calibration curve was prepared by serial dilution of alcoholic solution in distilled water to have four working aqueous solutions (10, 20, 35, and 60 µg/ml). The absorbance was measured in the range of 200 to 600 nm. Rutin nanocystals, spanlastic-free, and rutin's spanlastic colloidal dispersion were suitably diluted and measured immediately at 257 nm (all samples were measured in triplicate). The percent entrapment efficiency (%EE) and loading capacity (%LC) were calculated according to the following formulas [32, 33]:1\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\mathrm{\%}\mathrm{E}\mathrm{E}=\frac{amount\, of \, rutin \, entrapped \, in \, spanlastic}{Total \, amount \, of \, rutin \, added}\times 100$$\end{document}2\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\mathrm{\%}\mathrm{L}\mathrm{C}= \frac{amount \, of \, rutin }{total \, amount \, of \, ingredients \, of \, the \, formula (including \, rutin)}\times 100$$\end{document} The Energy Band gap (Eg) of the synthesized rutin-spanlastic, rutin nanocrystals, drug-free-spanlastic, in addition to pure rutin, was estimated using the UV–Vis-NIR Spectroscopy (Tauc plot) (Shimadzu UV–VIS spectrophotometer, UV-1900I, Japan) according to the following equation:3\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\sqrt[n]{\alpha {h}_{v}}=A\times {h}_{v}-{E}_{g}$$\end{document}where: α: absorption coefficient (cm−1). hv: Photon energy calculated as \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\frac{1240}{{\lambda \left( {nm} \right)}} eV$$\end{document}. Eg: Optical band gap energy. A: Constant. n (exponent): Determines the nature of the electronic transition (n = 1/2 direct allowed transition and n = 2 for indirect allowed transition). In-vitro dissolution studies and release kinetics The dissolution study was carried out using a USP II paddle dissolution tester, water (apparatus II, COPLEY, England), for rutin, rutin spanlastic, and rutin nanocrystals, with a paddle speed of 100 rpm at 37 ± 0.5 °C in 500 ml of 0.5% SDS (equivalent to 40 mg rutin). Aliquots of samples were withdrawn at regular intervals of time (10, 20,30, 40, and 60 min), which were replaced immediately by the same amount of fresh medium. The samples were filtered by a 0.45 μm syringe filter before measuring their absorbance spectrophotometrically in the range of 300–700 nm. The interfering effect of excipients on the maximum absorption (λmax) was tested by scanning the spectrum of each excipient alone as well as in combination with Rutin. The % dissolution efficiency was calculated according to the following equation [34, 35]:4\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\% {\text{DEt = }}\left( {\mathop \int \limits_{0}^{t} \frac{{Y_{t} dt}}{{Y_{100} T}}} \right) \times 100$$\end{document} The results of the in-vitro dissolution study of rutin, rutin spanlastic, and rutin nanocrystals were fitted mathematically with kinetic equations (zero order, first order, Higuchi model, Korsmeyer-Peppas model, and Hixson-Crowell cube root law). The coefficient of correlation (R2) was calculated for the linear curves obtained by regression analysis of the plots (using the Microsoft Excel program) [36]. The Korsmeyer-Peppas model is a widely used power-law formula, describing drug release from polymeric systems, accounting for diffusion, swelling, and erosion. The calculated slope (n value) is employed to identify the mode of drug release [35]: Exponent (n) value: Mechanism Identification of the Korsmeyer-Peppas model. n ≤ 0.45: (Fickian Diffusion): Drug release is governed by simple diffusion. 0.45 ≤ n ≤ 1.0: (Non-Fickian/Anomalous Transport): Combination of diffusion and polymer relaxation/erosion. n = 1: (Case-II Transport): Zero-order release; driven by erosion/relaxation. n > 1: (Super Case-II Transport): Accelerated release. The morphology and particle size of rutin spanlastic were estimated utilizing the transmission electron microscope (TEM) (JEM1400, JEOL Ltd., Tokyo, Japan). The sample was applied to a membrane-coated grid surface via filter paper. It was negatively stained with uranyl acetate dye for 3 min and dried at room temperature before being placed under the microscope to examine rutin spanlastic, while the nanocrystal sample was examined without staining. The scanning electron microscope (SEM) was employed to determine the particle size, surface characteristics, and morphology of rutin nanocrystals. The colloidal nanocrystals were transferred to a clean, dry glass slide for complete drying. The dried powder was transferred to a copper stub, and then the sample was coated with gold for one minute using a field emission scanning electron microscope (JEOL, JSM-6510LV, Japan). The sample was examined at various magnifications (10 kV electron acceleration). Furthermore, the functional groups were identified with the aid of FTIR analysis FTIR Perkin Elmer Fourier transform spectrometer, BRUKER, USA), and an air-cooled deuterated triglycine sulfate detector. A brief sample (rutin, spanlastic free, rutin spanlastic, and rutin nanocrystals) was mixed with KBr in a ratio of 1:100 and hydraulically compressed into a disc. The disc was examined across the wavelength range -4000 to -400/ cm. Assay for antioxidant activity DPPH radical scavenging The DPPH (2,2-Diphenyl-1-picrylhydrazyl) radical scavenging experiment was carried out following the procedure outlined in [37] for rutin, rutin nanocrystals, and rutin spanlastic at different doses (1.95, 3.9, 7.8, 5.63, 31.25, 62.5, 125, 250, 500, and 1000 µg/ml). Using the following formula, the percentage of DPPH scavenging effect was calculated (n = 3):\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\mathrm{DPPH}}\,{\text{scavenging }}\left( \% \right) = {\mathrm{A}}0 - {\mathrm{A1}}/{\mathrm{A}}0 \times {1}00$$\end{document}where A0 is the absorbance of the control response, and A1 is the absorbance when a test or reference sample is present. The reference chemical in this case was ascorbic acid. A graph presenting the concentration of the sample essential to scavenge 50% of the DPPH free radicals (n = 3) was used to achieve the IC50 value. ABTS radical scavenging With minor modifications, ABTS ((2,2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonic) acid) radical scavenging activity was determined for rutin, rutin nanocrystals, and rutin spanlastic at various doses (1.95, 3.9, 7.8, 5.63, 31.25, 62.5, 125, 250, 500, and 1000 µg/ml) in accordance with [38]. After six minutes of incubation, the absorbance at 734 nm was measured using a UV/visible spectrophotometer (UV–VIS Milton Roy). This formula was used to evaluate the levels of antioxidant activity:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\mathrm{ABTS}}\,{\mathrm{scavenging}}\left( \% \right) = \left( {{\mathrm{A}}\,{\mathrm{control}} - {\mathrm{A}}\,{\mathrm{sample}}} \right)/{\mathrm{A}}\,{\mathrm{control}} \times {1}00$$\end{document} A control = Negative control Absorption. A sample = Sample absorbance after six minutes. Gallic acid was used as a reference chemical. A graph presenting the concentration of the sample essential to scavenge 50% of the ABTS free radicals (n = 3) was used to achieve the IC50 value. Atitumar activity against breast cancer MCF-7 cell line Viability test Antitumor efficacy of rutin, rutin nanocrystals, and rutin spanlastic was confirmed in a viability assay against the breast cancer cell line. The MCF-7 human breast cancer model routinely utilized was obtained from the American Type Culture Collection (ATCC; USA) and cultured from the National Cancer Institute (NCI; Cairo, Egypt). Cells were subcultured in Dulbecco's Modified Eagle Medium (DMEM; Gibco, USA) with 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Lonza, Switzerland). Cultures were incubated at 37 °C in a humid incubator with 5% CO₂ [39]. The reagents listed above were all of cell-culture quality. Cell density in the medium was 5 × 104 cells/well. Rutin, rutin nanocrystals, and rutin spanlastic were then introduced to the cells after 24 and 48 h of exponential phase growth (0, 100, 200, 300, 400, 500, and 600 µg/ml). The 12 mM stock solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (10 µl) (Vybrant® MTT Cell Proliferation Assay Kit) was then added to all wells. Then 50 µl of DMSO was added to each well after the mixture was properly mixed with the pipette. It was incubated at 37 °C for 10 min. Absorbance was measured on a Bio-Tek Instruments Inc. (Santa Clara, CA, USA) ELx 800 microplate reader at 540 nm [39]. Absorbance values for untreated control cells correspond to 100% of cell viability. The following formula represents the optical densities of the treated cells (A) and the untreated cells (B):\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\mathrm{Cell}}\,{\mathrm{viability}}\left( \% \right):\,\left( {{\mathrm{A}}/{\mathrm{B}}} \right) \times {1}00$$\end{document} The IC₅₀ value was calculated from the dose–response curve plotted from triplicate measurements. Analysis of cell cycles Using flow cytometric examination of the IC50 values found by the MTT test (incubation for 48 h), the cell-cycle distribution of the MCF-7 breast cancer cell line was examined following treatment with rutin, rutin nanocrystals, and rutin spanlastic (IC50 = 333.69, 106.95, and 42.45 µg/ml, respectively). The culture medium was carefully withdrawn after the cells were stimulated with rutin, spanlastic-free, rutin spanlastic, and rutin nanocrystals. PBS was then added, and the mixture was gently shaken before the PBS was removed. After being introduced and thoroughly mixed, 1 ml of trypsin was left to digest in the incubator. The cells were taken out of the incubator and put in a 3 ml container to complete the trypsin digestion process. The cells were resuspended and added to the centrifuge tube using a pipette. Centrifugation was then used to remove the supernatant at room temperature for five minutes at 1000 rpm [40]. Three milliliters of PBS resuspension cells were then added. Following their resuscitation with 75% alcohol, the cells were kept at 4 °C overnight. Then, the supernatant was collected following centrifugation at 1000 rpm for 5 min at room temperature. After three PBS washes, the cell cycle was analyzed using flow cytometry (BD AccuriTM C6 Plus Flow Cytometer). The cells were stained with a propidium iodide staining solution for 30 min at 37 ◦C [40]. AccuriTM C6 software from BD Biosciences approximated the proportion of cells in each cell-cycle phase. Assay for annexin-V/PI double-staining The exponential growth phase cells (incubation for 48 h) were put into a well plate, stimulated by rutin, rutin nanocrystals, and rutin spanlastic (IC50 = 333.69, 106.95, and 42.45 µg/ml, respectively). After the cells were collected, the culture medium was slurped into the centrifuge tube, 1 ml of 1 × Binding Buffer was used to clean the cells, and 100 µl of 1 × Binding Buffer was used to resuspend the cell pellet. The cells were then centrifuged for 10 min at 300 × g. Following that, 10 µl of annexin-V tagged with a fluorescent dye (annexin V-FITC) was added to every 106 cells. The mixture was properly mixed, and the cells were incubated for 15 min at room temperature without light. Each of the 106 cells was then given 500 µl of 1 × Binding Buffer for a second washing. Following that, the cells were centrifuged at 300 × g for ten minutes. After, 1 × Binding Buffer (500 µl) was used to resuspend the cell pellet. Finally, just before analysis using the BD AccuriTM C6 Plus Flow Cytometer, 5 µl of propidium iodide solution was added [41]. Determination of caspase 3 activity The exponential growth phase cells (incubation for 48 h) were placed in a well plate and stimulated by rutin, rutin nanocrystals, and rutin spanlastic. Caspase 3 Activity was estimated by Caspase 3 Activity Assay Kit (Colorimetric), NBP2-54,838–100 Assays, Novus Biologicals LLC, a Bio-Techne Brand, as per the manufacturer’s protocol using HiPo MPP-96 Microplate. Statistical analysis Mean values ± standard deviation (SD) were employed to represent the data. The differences among the groups were determined by one-way ANOVA and Tukey’s multiple comparison test. The significance level of p < 0.05 was employed to establish the significance of the differences observed. Multiple group statistical analysis was conducted using GraphPad Prism software, version 9 (GraphPad Software Inc., La Jolla, CA, USA). The Student t-test was used to establish the significant differences in %DR and dissolution kinetics (Microsoft Excel program). Results Characterization of spanlastic and nanocrystals formulation The UV spectrum of aqueous rutin solution exhibits four absorption maxima around 204, 257, 265, and 355 nm (Fig. 1). The UV absorbance measured at ʎmax 257 nm for the calibration curve of rutin (10 to 60 µg/ml), a linear curve was obtained with a regression equation of (y = 0.0397x–0.0494) and R2 of 0.9998 which indicated the goodness of fit of the calibration curve.Fig. 1UV spectrum (absorbance versus wavelength) in the range of 200–600 nm of different concentrations of rutin (10, 20, 40, and 60 µg/ml) showing two maximum absorption peaks: ʎmax 2 (band II) at 257 nm and ʎmax 1 (band I) at 355 nm UV spectrum (absorbance versus wavelength) in the range of 200–600 nm of different concentrations of rutin (10, 20, 40, and 60 µg/ml) showing two maximum absorption peaks: ʎmax 2 (band II) at 257 nm and ʎmax 1 (band I) at 355 nm The Tauc plot method was employed to determine the optical bandgap energy, providing insight into the electronic environment and drug state within the formulations (Fig. 2). The pure rutin exhibited a bandgap of 2.87 eV. The rutin spanlastics demonstrated a bandgap of 3.04 eV, rutin nanocrystals exhibited a bandgap of 2.94, and spanlastics-free showed the highest value of 4.65 eV (Table 1).Fig. 2Bandgap energy determination of rutin and its formulations. A rutin, B rutin spanlastic, C rutin nanocrystal, and D spanlastic free. The X-axis represents the photon energy (hν, eV), and the Y-axis represents (αhν)2. The bandgap energy was calculated by extrapolating the linear portion of the plot to the X-axisTable 1Band Gap calculation using a Tauc plot method and % drug released for rutin, rutin spanlastic, spanlastic free, and rutin nanocrystalFormulationBandgap (eV)R2 (Tauc)*% DR(Mean ± SD)*%DE(Mean ± SD)Dissolution modelRutin2.870.998221.97 ± 0.6017.99 ± 1.55Korosmeyers-Peppas (n = 1.09 & R2 = 0.9068)Rutin spanlastic3.040.999788.63 ± 13.0×#71.24 ± 5.76×#Korosmeyers-Peppas (n = 2.44& R2 = 0.8102)Rutin nanocrystals2.940.992745.5 ± 0.67×34.66 ± 0.3×First order (R2 = 0.9758)Spanlastic- free4.650.9502–––*%DR: Rutin released after 60 min, %DE: %Dissolution efficiency, Transport Mechanism: according to Korsmeyers-peppas model and the calculated value of n and R2. ×significant difference of rutin (Student T test P < 0.05) and #significant difference between rutin nanocrystals and rutin spanlastic (Student T test P < 0.05) Bandgap energy determination of rutin and its formulations. A rutin, B rutin spanlastic, C rutin nanocrystal, and D spanlastic free. The X-axis represents the photon energy (hν, eV), and the Y-axis represents (αhν)2. The bandgap energy was calculated by extrapolating the linear portion of the plot to the X-axis Table 1Band Gap calculation using a Tauc plot method and % drug released for rutin, rutin spanlastic, spanlastic free, and rutin nanocrystalFormulationBandgap (eV)R2 (Tauc)*% DR(Mean ± SD)*%DE(Mean ± SD)Dissolution modelRutin2.870.998221.97 ± 0.6017.99 ± 1.55Korosmeyers-Peppas (n = 1.09 & R2 = 0.9068)Rutin spanlastic3.040.999788.63 ± 13.0×#71.24 ± 5.76×#Korosmeyers-Peppas (n = 2.44& R2 = 0.8102)Rutin nanocrystals2.940.992745.5 ± 0.67×34.66 ± 0.3×First order (R2 = 0.9758)Spanlastic- free4.650.9502–––*%DR: Rutin released after 60 min, %DE: %Dissolution efficiency, Transport Mechanism: according to Korsmeyers-peppas model and the calculated value of n and R2. ×significant difference of rutin (Student T test P < 0.05) and #significant difference between rutin nanocrystals and rutin spanlastic (Student T test P < 0.05) Band Gap calculation using a Tauc plot method and % drug released for rutin, rutin spanlastic, spanlastic free, and rutin nanocrystal *%DR: Rutin released after 60 min, %DE: %Dissolution efficiency, Transport Mechanism: according to Korsmeyers-peppas model and the calculated value of n and R2. ×significant difference of rutin (Student T test P < 0.05) and #significant difference between rutin nanocrystals and rutin spanlastic (Student T test P < 0.05) The % cumulative drug released was plotted against time (Fig. 3), showing a significant increase in % cumulative drug released from both rutin nanocrystal and rutin spanlatic in comparison to rutin, as indicated by the significant increase in %dissolution efficiency (%DE) and % drug released after 60 min (%DR). The % drug released from rutin spanlastic after 60 min was significantly different from that released from rutin nanocrystals (Table 1).Fig. 3%Cumulative drug release of rutin, rutin spanlastic, and rutin nanocrystal in 0.5% SDS dissolution medium. The X-axis represents time (minutes), while the Y-axis represents the percentage of cumulative rutin released. Data are presented as mean ± SD (n = 3) %Cumulative drug release of rutin, rutin spanlastic, and rutin nanocrystal in 0.5% SDS dissolution medium. The X-axis represents time (minutes), while the Y-axis represents the percentage of cumulative rutin released. Data are presented as mean ± SD (n = 3) The dissolution kinetics were estimated by fitting the dissolution data to different dissolution models using the Microsoft Excel program. The results indicated that the best fit of rutin dissolution data followed Korsmeyer-Peppas model (R2 = 0.9068) (super case II transport, (n = 1.09)). The dissolution data showed poor fitting to classical models; zero and first order models (R2 were 0.7535 and 0.7018, respectively). Rutin spanlastic dissolution data showed poor fitting also to zero, first, Hixson-Crowell and Huguchi models (R2 were 0.6901, 0.5995, 0.5841, and 0.741, respectively), the best fit (R2 = 0.8102) was for Krosmeyers-Peppas model showing super case II transport (n = 2.44). On the other hand, the rutin nanocrystal dissolution data were best fitted with a first-order dissolution model with R2 equal to 0.9758 (Table 1). The absorbance of rutin, spanlastic, and nanocrystals was measured, and the rutin concentration was determined. The %Entrapment efficiency (%EE) and % Drug Loading (%DL) were calculated (Table 2). The average drug content was 3.55 ± 0.07 mg/ml and 3.43 ± 0.02 mg/ml for rutin spanlastic and rutin nanocrystal, respectively. The % EE was 88.81 ± 1.83% for rutin spanlastic and 85.79 ± 0.53% for rutin nanocrystals. While the %DL was 3.78 ± 0.08% and 24.51 ± 0.15% for rutin spanlastic and rutin nanocrystal, respectively. The hydrodynamic diameter of rutin spanlastic ranged from 100.6 to 101.6 nm with an average particle size of 101.06 ± 0.503 nm and average zeta potential of -34.05 ± 7.7 mV, while rutin nanocrystal ranged from 272.9 to 752.3 nm with an average particle size of 504.83 ± 240.08 nm, and the average zeta potential was -34.87 ± 6.56 mV. The PDI was 0.1954 ± 0.004 and 0.614 ± 0.33 for rutin spanlastic and rutin nanocrystal, respectively (Table 2).Table 2Nanoparticles characterizationParameterSpanlasticNanocrystalsParticle size (nm)101.06 ± 0.503504.83 ± 240.08Zeta potential (mv)-34.05 ± 7.7-34.87 ± 6.56PDI0.1954 ± 0.0040.614 ± 0.33Drug content (mg/ml)3.55 ± 0.073.43 ± 0.02%EE88.81 ± 1.8385.79 ± 0.53%LC3.78 ± 0.0824.51 ± 0.15Data expressed as a mean ± SD (n = 3) Table 2Nanoparticles characterizationParameterSpanlasticNanocrystalsParticle size (nm)101.06 ± 0.503504.83 ± 240.08Zeta potential (mv)-34.05 ± 7.7-34.87 ± 6.56PDI0.1954 ± 0.0040.614 ± 0.33Drug content (mg/ml)3.55 ± 0.073.43 ± 0.02%EE88.81 ± 1.8385.79 ± 0.53%LC3.78 ± 0.0824.51 ± 0.15Data expressed as a mean ± SD (n = 3) Nanoparticles characterization Data expressed as a mean ± SD (n = 3) The TEM examination of rutin spanlastic illustrated smooth spherical dark vesicles, with a diameter ranging from 99.41 to 138.27 nm (Fig. 4). The TEM examination of nanocrystals demonstrated thin, elongated rod-shaped (Fig. 4). The SEM examination of rutin nanocrystals at 20 kV (magnification power 10,000) illustrated irregular, very thin flake-shaped aggregates (Fig. 4).Fig. 4TEM of A rutin spanlastic, B TEM of rutin nanocrystals, and C SEM of rutin nanocrystals TEM of A rutin spanlastic, B TEM of rutin nanocrystals, and C SEM of rutin nanocrystals The FTIR of rutin, rutin nanocrystal, spanlastic-free, and rutin spanlastic was examined. The FTIR spectrum of Rutin (Fig. 5) demonstrated a broad characteristic peak at 3425 cm−1, which stands for hydroxyl group stretching, two peaks at 2925 and 2856 cm−1, which stand for CH2 and CH stretching, respectively. Sharp peaks at 1660 cm−1 and 1649 cm−1, that related to C=O stretching and C=C aromatic ring stretching. The FTIR of rutin nanocrystals (Fig. 5) seems to be quite similar to the FTIR of rutin; however, the % transmittance was significantly decreased. The FTIR spectrum of spanlastic free (Fig. 5) showed a peak at 3430 cm−1 (with the lowest % transmittance), two peaks at 2925 and 2856 cm−1, and a strong, sharp peak at 1641 cm−1 that is related to the stretching vibration of the carbon–oxygen double bond (the ester functional group of both tween 80 and span 80). The FTIR of rutin spanlastic (Fig. 5) showed the same peaks of rutin in addition to the sharp peak at 1640 cm−1 (the sharpness of the peak indicated the stability of the spanlastic formulation).Fig. 5FTIR of rutin (A), rutin nanocrystals (B), spanlastic-free (C), and rutin spanlastic (D). The X axis represents the wave number cm−1, and y axis represents the % transmittance FTIR of rutin (A), rutin nanocrystals (B), spanlastic-free (C), and rutin spanlastic (D). The X axis represents the wave number cm−1, and y axis represents the % transmittance Assay for antioxidant activity DPPH radical scavenging The DPPH radical scavenging activity was measured to evaluate the antioxidant activity (Fig. 6). It was found that treatments with rutin, rutin spanlastic, and rutin nanocrystals produced concentration-dependent DPPH radical scavenging activity (Fig. 6). Rutin spanlastic showed more activity than rutin and rutin nanocrystals. Rutin, rutin spanlastic, and rutin nanocrystals had mean scavenging concentrations (IC50, indicating 50% of scavenging) of 24.98, 8, and 8.43 µg/ml, respectively, whereas ascorbic acid, a positive control, had an IC50 of 3.2 µg/ml (Fig. 6).Fig. 6Antioxidant activity A DPPH (Positive control: ascorbic acid) and B ABTS (Positive control: Gallic acid) of rutin, rutin spanlastic, and rutin nanocrystals. Results are expressed as a mean ± SD (n = 3). *means significant versus the control group. Each group differed significantly from the others at p < 0.05 Antioxidant activity A DPPH (Positive control: ascorbic acid) and B ABTS (Positive control: Gallic acid) of rutin, rutin spanlastic, and rutin nanocrystals. Results are expressed as a mean ± SD (n = 3). *means significant versus the control group. Each group differed significantly from the others at p < 0.05 ABTS radical scavenging The antioxidant impact of the rutin spanlastic was higher than that of rutin and rutin nanocrystals, and the ABTS assay findings were similar to those of the DPPH assay (Fig. 6). The ABTS scavenging assay's IC50 values were determined to be 116.82, 56.82, and 63.51 for Rutin, rutin spanlastic, and rutin nanocrystals, respectively. Gallic acid, a positive control, had an IC50 of 3.65 µg/ml (Fig. 6). Rutin, rutin nanocrystals, and rutin spanlastic viability test revealed their anticancer efficacy against breast cancer MCF-7 cell line Figure 7 presents the viability and inhibitory effect of rutin, rutin nanocrystals, and rutin spanlastic on a breast cancer cell line (MCF-7) incubation for 24 and 48 h, with IC50 values of (486.74, 230.31, and 129.94 µg/ml) and (333.69, 106.95, and 42.45 µg/ml), respectively. Rutin, rutin nanocrystals, and rutin spanlastic have antitumor activity against the MCF-7 cell line at different concentrations, with special reference to rutin spanlastic nanoparticles, which have the lowest viability and the highest inhibition (Fig. 7).Fig. 7Effect of rutin, rutin nanocrystals, and rutin spanlastic on MCF-7 cell line using MTT viability test (incubation for 24 and 48 h). A rutin (IC50 = 486.74 and 333.69 µg/ml for 24 and 48 h, respectively). B rutin nanocrystals (IC50 = 230.31 and 106.95 µg/ml for 24 and 48 h, respectively). C rutin spanlastic (IC50 = 129.94 and 42.45 µg/ml for 24 and 48 h, respectively. Data are expressed as mean ± SD, n = 3 Effect of rutin, rutin nanocrystals, and rutin spanlastic on MCF-7 cell line using MTT viability test (incubation for 24 and 48 h). A rutin (IC50 = 486.74 and 333.69 µg/ml for 24 and 48 h, respectively). B rutin nanocrystals (IC50 = 230.31 and 106.95 µg/ml for 24 and 48 h, respectively). C rutin spanlastic (IC50 = 129.94 and 42.45 µg/ml for 24 and 48 h, respectively. Data are expressed as mean ± SD, n = 3 Cell-cycle analysis The cell-cycle analysis of rutin, rutin nanocrystals, and rutin spanlastic, using flow cytometry, is shown in Fig. 8A–D, with different cell-cycle phases (SubG1, G0/G1, S, and G2/M) on the exponential growth phase of MCF-7 cells (incubation for 48 h). Different treatments indicated a G0/1-phase cell-cycle arrest with special reference to rutin spanlastic nanoparticles. Rutin spanlastic nanoparticles exposed a notable G0/1-phase cell-cycle arrest from 39.6% in untreated cancer cells to 88.1% in treated cells.Fig. 8Breast cancer cell line (MCF-7) cell-cycle distribution in untreated cancer cells (control) (A) and after treatments with rutin (B), rutin nanocrystals (C), and rutin spanlastic (D), was analyzed using flow cytometric analysis based on IC50 concentrations (333.69, 106.95, and 42.45 µg/ml, respectively) detected by MTT assay (incubation for 48 h) Breast cancer cell line (MCF-7) cell-cycle distribution in untreated cancer cells (control) (A) and after treatments with rutin (B), rutin nanocrystals (C), and rutin spanlastic (D), was analyzed using flow cytometric analysis based on IC50 concentrations (333.69, 106.95, and 42.45 µg/ml, respectively) detected by MTT assay (incubation for 48 h) Annexin V/PI double-staining The apoptotic cells influenced rutin, rutin nanocrystals, and rutin spanlastic were exposed by annexin-V/PI double staining on the exponential growth phase of MCF-7 cells (incubation for 48 h), as revealed in Fig. 9 A–D. Different treatments showed an increase in apoptotic cells with special reference to rutin-splastic nanoparticles. Rutin spanlastic nanoparticles demonstrated a remarkable rise in apoptotic activity from 1.5% in untreated cancer cells to 30.5% in treated cells.Fig. 9Estimation of apoptotic cell populations of breast cancer cell line (MCF-7), untreated cancer cells (control) (A) after treatments with rutin (B), rutin nanocrystals (C), and rutin spanlastic (D), determined by annexin V/PI double staining based on IC50 concentrations (333.69, 106.95, and 42.45 µg/ml, respectivly) detected by MTT assay using flow cytometry (incubation for 48 h). The lower-right quadrant showed early cells in apoptosis Estimation of apoptotic cell populations of breast cancer cell line (MCF-7), untreated cancer cells (control) (A) after treatments with rutin (B), rutin nanocrystals (C), and rutin spanlastic (D), determined by annexin V/PI double staining based on IC50 concentrations (333.69, 106.95, and 42.45 µg/ml, respectivly) detected by MTT assay using flow cytometry (incubation for 48 h). The lower-right quadrant showed early cells in apoptosis Caspase 3 activity Caspase 3 activity was exposed on the MCF-7 cell line, with the IC50 concentration determined via MTT viability tests for rutin, rutin nanocrystals, and rutin spanlastic (333.69, 106.95, and 42.45 µg/ml, with incubation for 48 h). In contrast to the control group, the MCF-7 cell line treated with rutin, rutin nanocrystals, and rutin spanlastics displayed a rise in the Caspase 3 activity (1.11-fold, 3.72-fold, and 6.94-fold, respectively) (Fig. 10). Furthermore, treatment with rutin spanlastics exposed a rise in Caspase 3 activity in comparison to rutin and rutin nanocrystals, being particularly active (Fig. 10).Fig. 10Caspase 3 activity of rutin, rutin nanocrystals, and rutin spanlastic using Caspase 3 Activity Assay Kit (Colorimetric) on the IC50 concentration detected by MTT viability test (IC50 = 333.69, 106.95, and 42.45 µg/ml, respectively, with incubation for 48 h). Data were expressed as mean ± SD (n = 3). ameans significant versus the control group and bmeans significant versus the rutin group. Control: cancer cell without any treatments. Each group differed significantly from the others at p < 0.05 Caspase 3 activity of rutin, rutin nanocrystals, and rutin spanlastic using Caspase 3 Activity Assay Kit (Colorimetric) on the IC50 concentration detected by MTT viability test (IC50 = 333.69, 106.95, and 42.45 µg/ml, respectively, with incubation for 48 h). Data were expressed as mean ± SD (n = 3). ameans significant versus the control group and bmeans significant versus the rutin group. Control: cancer cell without any treatments. Each group differed significantly from the others at p < 0.05 Discussion In the present study, we demonstrate for the first time that rutin-loaded elastic nanoparticles exhibit improved antioxidant and anticancer activity against MCF-7 breast cancer cells. This notable finding underscores the potential of elastic vesicle-derived nanocarriers as a means to overcome rutin's major limitations, including poor solubility, reduced absorbability, and rapid metabolism. The mean zeta potential was 34.05 ± 7.7 mV and -34.87 ± 6.56 mV for rutin spanlastic and rutin nanocrystals, respectively, representing adequate stability [42]. The negative zeta potential encountered here can be explained due to the adsorption of the tween on the surface of the nanoparticles, as the ester group might achieve a mild negative charge during aqueous surroundings; in addition, rutin, being a flavonoid glycoside, possesses the functional groups of hydroxyl (–OH) and carbonyl (C=O), capable of deprotonation during water, notwithstanding the lack of extensive ionization. The presence of aromatic rings rich in electrons existing in rutin might also contribute to the formation of a negative surface potential [12]. The polydispersity index of rutin spanlastic was adequately low (0.195 ± 0.003), hence affirming a stable particle distribution in the colloidal dispersion, a conclusion also substantiated from the observation via transmission electron microscopy (TEM). On the contrary, the polydispersity index of the nanocrystals showed relatively high indices (0.613 ± 0.33), hence revealing a non-uniform particle size distribution within the specimen [43]. The scanning electron microscope SEM can examine the sample surface utilizing the scattered electrons and can visualize a large sample size; consequently, SEM was selected to examine the nanocrystals according to its solid massive nature. On the other hand, the transmission electron microscope (TEM) depends on electron transmission through a very thin layer of sample and enables the visualization of the internal structure [44]. The TEM examination of nanocrystals confirms the presence of rutin in the form of very thin flakes (> 100 nm thick). The FTIR of rutin nanocrystals was identical to the FTIR of rutin, which can be explained as nanocrystals are exclusively composed of the active ingredient without any carrier, which enhances its stability. On the other hand, the FTIR of rutin spanlastic was almost identical to rutin FTIR except for the presence of a characteristic sharp peak, which is related to the stretching vibration of the carbon–oxygen double bond existing in both span 80 and tween 80. The bandgap energy (Eg) of rutin and rutin nanocrystals was almost the same (Eg = 2.87 eV, R2 = 0.9982, and Eg = 2.94 eV, R2 = 0.9927, respectively. The excellent linear fit (R2 > 0.99) indicates a well-defined direct transition and illustrates the intrinsic semiconductor-like properties of rutin. The minimal change in bandgap of rutin nanocrystals suggests the minimal chemical interaction and indicates the preservation of the drug's electronic structure (which was confirmed with its FTIR spectrum). It could indicate quantum confinement effects (particle size in the nanoscale) or surface states, meaning that enhancing solubility without altering the electronic properties. The rutin nanocrystal showed improvement in dissolution after 60 min (25.61–47.50%). The preserved electronic structure (minimal bandgap shift) confirms the drug remains in its crystalline form, just with reduced particle size. Enhanced dissolution is primarily due to increased surface area (Noyes-Whitney equation), not molecular-level changes. This is a physical modification strategy with predictable outcomes [45]. Rutin nanocrystal dissolution data were best fitted to a first-order model. A process where the rate of drug release is directly proportional to the amount of drug remaining in the dosage form, leading to a concentration-dependent, exponential decrease over time. Nanocrystals might provide more sustained release due to slower dissolution kinetics [46]. The calculated bandgap of spanlastic-free showed a high value of Eg = 4.65 eV, suggesting this system acts as a wide-bandgap material, while lower R2 (9502) indicated possible scattering or multiple transitions. The significant bandgap shift of rutin spanlastic (2.87 → 3.04 eV) indicates strong drug-carrier interaction, meaning that the possibility of the existence of rutin in the molecular dispersion in lipid bilayer or charge transfer complexes formation. The intermediate bandgap suggests the drug is neither fully in its crystalline form nor completely dissolved in the carrier. It's likely molecularly dispersed with some interaction. The R2 value of 0.9997 indicates a high-quality measurement [47]. Rutin spanlastic illustrated a significant bandgap change, with significant improvement in dissolution (from 25.61 to 95.9%). The intermediate bandgap (between pure drug and empty carrier) indicates molecular dispersion with interactions. This electronic structure change correlates with amorphization/molecular dispersion of the drug. The drug is likely dispersed at the molecular level in the lipid bilayer, eliminating lattice energy barriers to dissolution. The bandgap energy analysis confirmed a significant shift in the electronic state of the drug upon loading into the spanlastic matrix. This finding is in strong agreement with the FTIR spectroscopic data, which provided complementary evidence for a specific molecular interaction between the drug and the vesicle components. Rutin spanlastic showed better fit to Krosmyeres-Peppas (super case II transport from spherical matrix). The enhanced dissolution can be explained according to the sigmoid dissolution curve into 3 phases. In the first phase (lag), the spherical vesicles absorb water. The bilayer swells and becomes unstable, with little drug released. The second phase (accelerated breakdown), no erosion of vesicles, which is confirmed by poor fitting to the Hixson-Crowell fit (R2 = 0.584), but rather an explosive rupture (due to an increase in the internal pressure). The third phase (rapid release). This mechanism is fundamentally different from the dissolution observed for the pure Rutin (n = 1.09, planar geometry) [48, 49]. It has been widely reported that the bandgap energy (Eg) of semiconductor particles is inversely proportional to their particle size when in the nanoscale range. This phenomenon means that as the particle size decreases, the bandgap energy increases. According to TEM examination and particle size (101.06 ± 0.503 nm and 504.83 ± 240.08 for rutin spanlastic and rutin nanocrystals, respectively), it was found that a good correlation can be expected with the increase in bandgap energy, which reflects the magnitude of particle size [47]. In the present study, DPPH and ABTS radical scavenging activity were used to evaluate the antioxidant activity. It was found that rutin, rutin spanlastic, and rutin nanocrystals all have antioxidant activity at different concentrations as compared to the positive controls, ascorbic acid and gallic acid, respectively. The relation between cancer and the antioxidant effect of natural products is important [50], as reactive oxygen species (ROS) can damage lipids, nucleic acids, and proteins and alter their functions; upon the interruption between ROS formation and antioxidative defense, an oxidative stress condition is formed, which induces many diseases [3]. Antioxidant properties are also important for antitumor effects because they can remove free radicals, reduce oxidative injury, and regulate redox-sensitive signaling pathways, such as PI3K/Akt, MAPK, and NF-κB. Antioxidants can also suppress cancer cell growth by restoring redox balance. In addition, some bioactive compounds have dual properties because they can act as antioxidants in physiological environments and trigger pro-oxidant stress selectively in cancer cells, which can increase their cytotoxic effects. Consequently, antioxidant properties are often closely linked to antitumor properties, especially in formulations that target oxidative stress-mediated cellular mechanisms [51, 52]. Preclinical evidence shows that nanoparticles like liposomes, polymeric nanoparticles, metal–organic frameworks, and other nanoforms have the ability to encapsulate and deliver antioxidants to tumor cells with high efficacy and low systemic toxicity. Stimuli-responsive carriers containing mechanisms of tumour targeting further enhance the delivery of antioxidants. Evidence shows that such methods preserve normal cells, mitigate oxidative stress-related injury, and enhance the efficacy of treatment [53]. We employed MCF-7, an estrogen- and progesterone-receptor-positive human breast adenocarcinoma cell line that was initially purified from a pleural effusion and broadly used as a model representative of luminal, hormone-responsive breast cancer [54]. Recent research demonstrates that MCF-7 cells are capable of presenting phenotypic and metabolic heterogeneity in different situations, including co-culture with stroma cells or drug-resistant development, consequently highlighting their value to assess emerging anticancer agents [55]. Viability test revealed the anticancer efficacy of the rutin, rutin nanocrystals, and rutin spanlastic against the breast cancer MCF-7 cell line; viability test reflects the amount of live cells present; when the drug is potent as an anticancer, the amount of live cells becomes smaller; notably, the lowest amount of live cells was for rutin spanlastic. Furthermore, the current results of the viability test indicated that free spanlastic nanoparticles and rutin were effective, and when combined, a synergistic effect of spanlastic free and rutin in the viability test was noted. Naturally occurring flavonoids are known to have anti-cancer and antioxidant properties. Grigalius and Petrikaite [56] sought to identify if antioxidant and anticancer activities were related to anticancer activity through inhibition of the growth of cancer cells. The experiments were conducted using the MTT assay on three human cancer cell lines (lung (A549), breast (MCF-7), and brain epithelial (U87)). Also, antioxidant activity was quantified by the DPPH radical scavenging assay. At least one of the screened cancer cell lines was found to be sensitive to the anticancer activities of thirteen trihydroxyflavones. Their activity on the MCF-7 cell line was higher, whereas their activity on the U87 cell line was the least, and 3', 4', 5-trihydroxyflavone 7 was the most active compound. The superior anticancer effects of rutin spanlastic over rutin nanocrystals can be explained by the particle size difference, in addition to the elastic nature of spanlastic vesicles (due to the presence of edge activator). Moreover, the flexible vesicles improve membrane interaction and penetration, enhancing the bioavailability. Nanocrystals are composed of 100% pure drug, but they may require a higher drug concentration to show their efficacy. Nanocrystals may enhance the solubility but may not enhance the permeability, such as spanlastic, which may improve both the paracellular and transcellular pathways. Spanlastic shows superior entrapment for lipophilic drugs such as rutin, when compared to nanocrystals by offering sustained release and extended action [57, 58]. In the same context, the cell-cycle analysis, annexin-V/PI double staining, and Caspase 3 activity of rutin, rutin nanocrystals, and rutin spanlastic were determined on the exponential growth phase of MCF-7 cells (incubation for 48 h). The results indicated that all treatments stop cell division, which is characteristic of cancer cells' death, with special reference to rutin spanlastic nanoparticles. Cell cycle arrest during pivotal checkpoints has been an effective therapeutic regimen to eliminate the growth of cancer cells. Cell cycles of mammals also include G1, S, G2, and M phases, with G1 and G2 phases being the RNA-synthesizing phase and protein-synthesizing phase, respectively, while S is DNA replication, and M is segregation of the chromosomes [12]. Different plant-derived anticancer agents, such as flavonoids and vinca alkaloids, function by disrupting critical cell cycle regulators [12]. An intracellular program mediates the mechanism of cell suicide known as programmed cell death (PCD). When homeostasis is upset, PCD balances cell survival and death and triggers many signal pathways [59]. The series of actions that results in the systematic and regulated devastation of cells is known as PCD [60]. PCD is essential for both animal development and tissue homeostasis. It is now well recognized that a wide range of human illnesses, including cancer, are linked to aberrant control of this mechanism [61]. One of the two main roles of the cell death mechanism is to act as an antagonist in mitotic cell division, preventing excessive cell elimination, and the second is to eliminate mutated cells as a preventative measure in illnesses like cancer. A key strategic approach to cancer prevention and therapy is currently the induction of cell death by various kinds of PCD, which also inhibits cell growth [62]. Several studies were done with the general theme of cancer treatment being the induction of apoptosis, and several articles claimed that flavonoids were promising agents capable of inducing apoptosis in cancer cells. Since the flavonoids are mostly non-toxic molecules, flavonoids may minimize the harmful effects associated with the toxic medicines generally used in the treatment of cancer [63, 64]. Preclinical and epidemiological studies equally reinforce the protective effect of dietary flavonols, flavones, and isoflavones against ovarian cancer prevention. Though flavonoids are a heterogeneous and complex class of naturally occurring polyphenolic molecules, phytochemicals have been effective in the prevention and treatment of cancer [65]. Our results confirm the hypothesis that enhanced delivery of rutin does more than just provide improved solubility but also improved cellular incorporation and therapeutic efficacy, providing a dual benefit more rarely seen with nanocrystals, which boost solubility but do not achieve an increase in permeability. One of the strengths of the current research is the thorough characterization of both drug products with a variety of analytical techniques (FTIR, TEM, SEM, electronic bandgap energy, and dissolution behavior), which gave considerable confirmation of their characteristics. A limitation of the current study was almost entirely focused on in vitro assays with a single breast cancer cell line (MCF-7); hence, a requirement for follow-up in vivo experiments and investigations on a larger number of breast cancer subtypes, including triple-negative forms, to validate these outcomes. The results from the present study suggest that spanlastic vesicles have potential capability as an expandable delivery vehicle to increase the therapeutic efficacy of poorly water-soluble flavons (rutin); accordingly, future investigations should focus on targeted delivery devices such as ligand-functionalized spanlastics, in vivo pharmacokinetic profiles, and long-term toxicity tests. Conclusion The current research revealed that nanotechnology-based carriers were capable of effectively enhancing the therapeutic capability of rutin. Among all the tested preparations, rutin spanlastic nanoparticles exhibited superior antioxidant capacity, marked inhibition of MCF-7 breast cancer cells' viability, induction of cell-cycle arrest, and induction of apoptosis (annexin-V/PI double staining and Caspase 3 activity) in comparison with rutin or rutin nanocrystals separately. The aforementioned effects can be attributed to the ultrasmall particle size, elastic vesicles, and enhanced membrane interaction due to spanlastic vesicles, which collectively enhance permeability and bioavailability. Similarly, this research introduces the correlation of electronic bandgap energy with dissolution behavior as a novel characterization approach for nanocarrier systems. In the context of spanlastics, a measurable change in the bandgap of the encapsulated drug signifies a disruption in its native crystalline order and a change in its intermolecular interactions within the vesicular matrix. These electronic structure modifications directly influence dissolution dynamics, thereby enabling bandgap energy to serve as a predictive metric for particle size and the strength of drug-excipient interactions that underpin release profiles. Additional in vivo and clinical investigations should validate these advantages and determine the mechanisms suggested herein.